Patent · US Active

Antifibrotic activity of GAS6 inhibitor

US10876176B2 · kind B2 · utility

2Cited by

6References

4Claims

0Family size

Assignees

ARAVIVE BIOLOGICS, INC. · US
The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Raymond Tabibiazar · Portola Valley, US
Amato J. Giaccia · Stanford, US
Mihalis Kariolis · South San Francisco, US
Yu Miao · Sunnyvale, US

Key dates

Filing date	Dec 17, 2015
Grant date	Dec 29, 2020
Priority date	—
Expiry date	Dec 17, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/10001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.